Results 101 to 110 of about 28,421 (276)

The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy

Frontiers in Immunology
Despite significant advances in our knowledge regarding the genetics and molecular biology of gliomas over the past two decades and hundreds of clinical trials, no effective therapeutic approach has been identified for adult patients with newly diagnosed
A. A. Stepanenko, A. Sosnovtseva, Marat P Valikhov, Anastasia A. Chernysheva, Olga V. Abramova, Victor A. Naumenko, V. Chekhonin   +6 more
semanticscholar   +1 more source

Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review

Advanced Healthcare Materials, Volume 15, Issue 1, 9 January 2026.
This article reviews fluorescent hydrogel systems for cancer detection, monitoring, and therapy. Mimicking the tumor microenvironment, these hydrogels enable real‐time imaging and targeted drug delivery. The review discusses design strategies, labeling techniques, and applications, highlighting challenges and future opportunities in cancer diagnostics ...
Elahe Masaeli, Seshasai Srinivasan, Amin Reza Rajabzadeh   +2 more
wiley   +1 more source

Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma

Molecular Therapy: Oncolytics, 2019
As a clinical setting in which novel treatment options are urgently needed, hepatocellular carcinoma (HCC) exhibits intriguing opportunities for oncolytic virotherapy.
Yong Luo, Chaolong Lin, Wenfeng Ren, Fei Ju, Zilong Xu, Huiling Liu, Zeng Yu, Jun Chen, Jun Zhang, Pingguo Liu, Chenghao Huang, Ningshao Xia   +11 more
doaj   +1 more source

Attenuated Semliki Forest virus for cancer treatment in dogs : safety assessment in two laboratory Beagles [PDF]

, 2015
Background: Dogs suffer from spontaneous tumors which may be amenable to therapies developed for human cancer patients, and dogs may serve as large-animal cancer models.
Anttila, Marjukka O., Autio, Karoliina P. M., Hemminki, Akseli, Hinkkanen, Ari E., Niittykoski, Minna, Ruotsalainen, Janne J., Vähä-Koskela, Markus J. V., Waris, Matti   +7 more
core   +1 more source

In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy

Journal of Extracellular Vesicles, Volume 15, Issue 1, January 2026.
ABSTRACT Oncolytic adenoviruses (OVs) can directly eliminate cancer cells and subsequently activate immune responses, exhibiting potent antitumor therapeutics. However, it was observed that the immune cells can also be lysed during viral treatment, evidently dampening the OVs‐mediated antitumor immune response.
Tianye Wang, Sheng Zhao, Zao Ji, Zhonggui He, Zhenguo Cheng, Zhen Gu, Yuqi Zhang, Jin Sun, Funan Liu, Mengchi Sun   +9 more
wiley   +1 more source

Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer

Molecular Therapy: Oncolytics, 2023
Tumor antigen-driven responses to weakly immunogenic self-antigens and neoantigens directly affect treatment efficacy following immunotherapy. Using orthotopically grown SV40 T antigen+ ovarian carcinoma in antigen-naive wild-type or TgMISIIR-TAg-Low ...
Anna Mistarz, Marta Winkler, Sebastiano Battaglia, Song Liu, Alan Hutson, Hanna Rokita, Andrea Gambotto, Kunle O. Odunsi, Prashant K. Singh, A.J. Robert McGray, Jianmin Wang, Danuta Kozbor   +11 more
doaj   +1 more source

Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer [PDF]

, 2016
BACKGROUND: A major hurdle incurrent to the human clinical application of conditionally replicative adenovirus (CRAd)-based virotherapy agents is their limited therapeutic efficacy.
Ashshi, Ahmad Mohammad, Curiel, David T, Dmitriev, Igor P, El-Shemi, Adel Galal, Kashentseva, Elena A   +4 more
core   +2 more sources

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy

Cancer Cell International, 2021
It has been intensively reported that the immunosuppressive tumor microenvironment (TME) results in tumor resistance to immunotherapy, especially immune checkpoint blockade and chimeric T cell antigen therapy.
Yalei Zhang, Ye Li, Kun Chen, L. Qian, Peng Wang   +4 more
semanticscholar   +1 more source

Itaconate‐Related Gene Signatures as Prognostic Markers in Colon Cancer: Insights From Transcriptomic and Spatial Analysis

Human Mutation, Volume 2026, Issue 1, 2026.
Colon cancer is one of the most prevalent malignant tumors. Accurate evaluation of patient prognosis and optimization of treatment strategies continue to be major research focuses in colon cancer. Based on The Cancer Genome Atlas (TCGA) database, this study is the first to comprehensively analyze the expression, biological roles, and prognosis of ...
Tingting Zhang, Jianchao Meng, Qingyun Wang, Peng Zhang, Hui Li, Hailang Wei, Denggang Chen, Chen Bai, Sujit Nair   +8 more
wiley   +1 more source

Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis

Scientific Reports, 2021
Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem ...
Amanda W. K. AuYeung, Robert C. Mould, Ashley A. Stegelmeier, Jacob P. van Vloten, Khalil Karimi, J. Paul Woods, James J. Petrik, Geoffrey A. Wood, Byram W. Bridle   +8 more
doaj   +1 more source